Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hypersensitivity Reaction

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 41 articles:
HTML format



Single Articles


    January 2024
  1. QUINT JK, Shah PL
    What trials do and do not tell us about treatments for severe asthma.
    Lancet. 2024;403:224-226.
    PubMed    


  2. MAURER M, Ensina LF, Gimenez-Arnau AM, Sussman G, et al
    Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Lancet. 2024;403:147-159.
    PubMed     Abstract available


  3. MOUSSA S, Netchiporouk E
    Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
    Lancet. 2024;403:118-119.
    PubMed    


    December 2023
  4. DRUCKER NA, Cox CS Jr
    Adult presentation of congenital tracheooesophageal fistula treated as asthma and recurrent respiratory infections.
    Lancet. 2023;402:2326-2327.
    PubMed    


  5. JACKSON DJ, Heaney LG, Humbert M, Kent BD, et al
    Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
    Lancet. 2023 Dec 7:S0140-6736(23)02284-5. doi: 10.1016/S0140-6736(23)02284.
    PubMed     Abstract available


    November 2023
  6. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
    Lancet. 2023;402:1834.
    PubMed    


  7. DEVJANI S, Engel PV, Javadi SS, Smith B, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.
    Lancet. 2023;402:1833-1834.
    PubMed    


  8. GEDEON E, Henderson M, Leyland AH, Allik M, et al
    Association between care experience and mental health hospitalisation among children in Scotland, with a focus on chronic conditions (CHiCS): a population-wide longitudinal study using administrative data.
    Lancet. 2023;402 Suppl 1:S5.
    PubMed     Abstract available


  9. ALYAMI RA, Simpson R, Oliver P, Julious SA, et al
    Evaluation of the impact of letters to GP practices to promote asthma prescription uptake in school-age children during summer (TRAINS study): a pragmatic cluster-randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S22.
    PubMed     Abstract available


    September 2023
  10. HANOUNEH M, Arend LJ
    Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease.
    Lancet. 2023;402:1083-1084.
    PubMed    


    July 2023
  11. LEVY ML, Bateman ED, Allan K, Bacharier LB, et al
    Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective.
    Lancet. 2023 Jul 19:S0140-6736(23)01358-2. doi: 10.1016/S0140-6736(23)01358.
    PubMed    


    June 2023
  12. PETRUSHKIN H, Solebo AL
    Imaging inflammation in early-onset sarcoidosis: granulomatous anterior uveitis in a 7-year-old girl.
    Lancet. 2023;401:1963.
    PubMed    


    April 2023
  13. BILLARD MN, Bont LJ
    The link between respiratory syncytial virus infection during infancy and asthma during childhood.
    Lancet. 2023 Apr 19:S0140-6736(23)00672-4. doi: 10.1016/S0140-6736(23)00672.
    PubMed    


  14. ROSAS-SALAZAR C, Chirkova T, Gebretsadik T, Chappell JD, et al
    Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study.
    Lancet. 2023 Apr 19:S0140-6736(23)00811-5. doi: 10.1016/S0140-6736(23)00811.
    PubMed     Abstract available


  15. JAVAUD N, Gobert D
    Hereditary angioedema: is there a better future for treatment?
    Lancet. 2023;401:1054-1055.
    PubMed    


  16. CRAIG TJ, Reshef A, Li HH, Jacobs JS, et al
    Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023;401:1079-1090.
    PubMed     Abstract available


    February 2023
  17. AYGOREN-PURSUN E, Zanichelli A, Cohn DM, Cancian M, et al
    An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Lancet. 2023;401:458-469.
    PubMed     Abstract available


  18. RESHEF A, Grumach AS
    New medications to mitigate attacks of hereditary angioedema: does one size fit all?
    Lancet. 2023;401:413-415.
    PubMed    


    January 2023
  19. PORSBJERG C, Melen E, Lehtimaki L, Shaw D, et al
    Asthma.
    Lancet. 2023 Jan 19:S0140-6736(22)02125-0. doi: 10.1016/S0140-6736(22)02125.
    PubMed     Abstract available


    December 2022
  20. THYSSEN JP, Schmid-Grendelmeier P
    Long-term disease control in atopic dermatitis using biologics.
    Lancet. 2022 Dec 9:S0140-6736(22)02347-9. doi: 10.1016/S0140-6736(22)02347.
    PubMed    


  21. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Lancet. 2022 Dec 9:S0140-6736(22)02037-2. doi: 10.1016/S0140-6736(22)02037.
    PubMed     Abstract available


    September 2022
  22. PALLER AS, Simpson EL, Siegfried EC, Cork MJ, et al
    Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2022;400:908-919.
    PubMed     Abstract available


  23. HALLING AS, Thyssen JP
    Biological therapy for young children with atopic dermatitis.
    Lancet. 2022;400:867-869.
    PubMed    


    August 2022
  24. DESCAMPS V
    DRESS syndrome.
    Lancet. 2022;400:560.
    PubMed    


  25. JACKSON DJ, Bacharier LB, Gergen PJ, Gagalis L, et al
    Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
    Lancet. 2022;400:502-511.
    PubMed     Abstract available


  26. KELLY RS, Weiss ST
    Biologic therapies for asthma in underserved populations.
    Lancet. 2022;400:471-473.
    PubMed    


    July 2022
  27. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    PubMed     Abstract available


  28. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.
    PubMed    


    June 2022
  29. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    PubMed     Abstract available


  30. PERKIN MR
    Early introduction of allergenic food for all infants.
    Lancet. 2022;399:2329-2331.
    PubMed    


    May 2022
  31. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.
    PubMed    


    April 2022
  32. LOMMATZSCH M, Brusselle GG, Canonica GW, Jackson DJ, et al
    Disease-modifying anti-asthmatic drugs.
    Lancet. 2022;399:1664-1668.
    PubMed    


    March 2022
  33. CRAIG T, Magerl M, Levy DS, Reshef A, et al
    Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2022;399:945-955.
    PubMed     Abstract available


  34. FIJEN LM, Levi M
    Prophylaxis with anti-activated factor XII for hereditary angioedema.
    Lancet. 2022;399:889-890.
    PubMed    


    January 2022
  35. JONES SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, et al
    Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Lancet. 2022;399:359-371.
    PubMed     Abstract available


  36. GREENHAWT M, Shaker M, Abrams EM
    Peanut oral immunotherapy in very young children.
    Lancet. 2022;399:336-337.
    PubMed    


    October 2021
  37. ASHER MI, Rutter CE, Bissell K, Chiang CY, et al
    Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study.
    Lancet. 2021;398:1569-1580.
    PubMed     Abstract available


  38. PIJNENBURG MW, Nantanda R
    Rising and falling prevalence of asthma symptoms.
    Lancet. 2021;398:1542-1543.
    PubMed    


  39. JANKAUSKAITE L, Oostenbrink R
    Childhood lower respiratory tract infections: more evidence to do less.
    Lancet. 2021;398:1383-1384.
    PubMed    


  40. BUSH A, Pavord ID
    Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes.
    Lancet. 2021 Oct 14. pii: S0140-6736(21)02244.
    PubMed    


    August 2021
  41. SOAR J, Becker LB, Berg KM, Einav S, et al
    Cardiopulmonary resuscitation in special circumstances.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01257.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.